bioAffinity Technologies, Inc. (BIAFW) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
3300 NACOGDOCHES ROAD SAN ANTONIO, TX 78217 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 8731 - Commercial Physical and Biological Research (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 2,822 | 11,414 | |||
| Cash and cash equivalent | 2,822 | 11,414 | |||
| Inventory, net of allowances, customer advances and progress billings | 18 | 6 | |||
| Inventory | 18 | 6 | |||
| Prepaid expense | 297 | 460 | |||
| Other undisclosed current assets | 836 | 83 | |||
| Total current assets: | 3,973 | 11,962 | |||
| Noncurrent Assets | |||||
| Finance lease, right-of-use asset, after accumulated amortization | 1,166 | ||||
| Operating lease, right-of-use asset | 370 | ||||
| Property, plant and equipment | 459 | 214 | |||
| Intangible assets, net (including goodwill) | 2,238 | ||||
| Goodwill | 1,404 | ||||
| Intangible assets, net (excluding goodwill) | 833 | ||||
| Other noncurrent assets | 16 | 6 | |||
| Total noncurrent assets: | 4,249 | 220 | |||
| TOTAL ASSETS: | 8,222 | 12,182 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,755 | 887 | |||
| Accounts payable | 605 | 345 | |||
| Accrued liabilities | 1,150 | 542 | |||
| Deferred revenue | 33 | ||||
| Debt | 365 | 252 | |||
| Other undisclosed current liabilities | 95 | ||||
| Total current liabilities: | 2,248 | 1,139 | |||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 835 | ||||
| Long-term debt, excluding current maturities | |||||
| Finance lease, liability | 835 | ||||
| Liabilities, other than long-term debt | 283 | ||||
| Operating lease, liability | 283 | ||||
| Total noncurrent liabilities: | 1,118 | ||||
| Total liabilities: | 3,366 | 1,139 | |||
| Equity | |||||
| Equity, attributable to parent | 4,855 | 11,043 | |||
| Common stock | 66 | 59 | |||
| Additional paid in capital | 49,394 | 47,652 | |||
| Accumulated deficit | (44,604) | (36,667) | |||
| Total equity: | 4,855 | 11,043 | |||
| TOTAL LIABILITIES AND EQUITY: | 8,222 | 12,182 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Revenues | 7,900 | 5 | ||
| Cost of revenue | (0) | |||
| Gross profit: | 7,900 | 4 | ||
| Operating expenses | (10,506) | (4,015) | ||
| Other undisclosed operating loss | (5,368) | |||
| Operating loss: | (7,973) | (4,011) | ||
| Nonoperating income | 94 | 47 | ||
| Investment income, nonoperating | 122 | 47 | ||
| Other nonoperating income (expense) | (28) | |||
| Interest and debt expense | (37) | (2,100) | ||
| Loss from continuing operations before equity method investments, income taxes: | (7,916) | (6,064) | ||
| Other undisclosed loss from continuing operations before income taxes | (2,087) | |||
| Loss from continuing operations before income taxes: | (7,916) | (8,152) | ||
| Income tax expense | (21) | (2) | ||
| Loss from continuing operations: | (7,937) | (8,154) | ||
| Other undisclosed net income | 16,537 | |||
| Net income (loss): | 8,600 | (8,154) | ||
| Other undisclosed net loss attributable to parent | (16,537) | |||
| Net loss available to common stockholders, diluted: | (7,937) | (8,154) | ||
Comprehensive Income ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Net income (loss): | 8,600 | (8,154) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 8,600 | (8,154) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.